Inaleucel Added to WHO Recommended List as INN for oNKord®

20th April 2023 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has announced that Inaleucel has been added to the WHO recommended list as the international non-proprietary name (INN) oNKord®.This enables Glycostem to use inaleucel as the single identical INN worldwide, in pharmacopoeias, labelling, publications, drug regulation, advertising, and other promotional materials.

As of now, only two NK cell products have been INN listed, with inaleucel being the only cord blood stem cell derived one. This is a significant step forward for scalable, allogeneic, off-the-shelf cell therapies, as they can now become a reality.

Going forward, Glycostem will use oNKord® as the brand name, prominently displayed on the product bag label, external documentation, and communication such as investigator's brochures, corporate presentations etc. Meanwhile, inaleucel will be used on the product bag label and in external documentation, communication, and scientific articles, posters, abstracts, and presentations when referring to properties of the active substance (cells). It will be used in place of GTA002.

Click the link to download INN Recommended List 89 where inaleucel is published.